
EquitySector - HealthcareVery High Risk
Direct
NAV (14-Oct-26)
Returns (Since Inception)
Fund Size
₹6,861 Cr
Expense Ratio
1.31%
ISIN
INF109KC1GH2
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+3.86%
+11.12% (Cat Avg.)
3 Years
+20.39%
+19.56% (Cat Avg.)
5 Years
+15.00%
+13.08% (Cat Avg.)
Since Inception
+19.94%
— (Cat Avg.)
| Equity | ₹6,786.13 Cr | 98.91% |
| Others | ₹75.07 Cr | 1.09% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹788.06 Cr | 11.49% |
| Dr Reddy's Laboratories Ltd | Equity | ₹667.57 Cr | 9.73% |
| Cipla Ltd | Equity | ₹396.98 Cr | 5.79% |
| Biocon Ltd | Equity | ₹365.74 Cr | 5.33% |
| Mankind Pharma Ltd | Equity | ₹346.05 Cr | 5.04% |
| Alkem Laboratories Ltd | Equity | ₹330.36 Cr | 4.81% |
| Medplus Health Services Ltd | Equity | ₹295.65 Cr | 4.31% |
| Treps | Cash - Repurchase Agreement | ₹291.44 Cr | 4.25% |
| Cohance Lifesciences Ltd | Equity | ₹278.24 Cr | 4.06% |
| Divi's Laboratories Ltd | Equity | ₹259.25 Cr | 3.78% |
| Syngene International Ltd | Equity | ₹240.3 Cr | 3.50% |
| Net Current Assets | Cash | ₹-216.78 Cr | 3.16% |
| Dr Agarwal’s Health Care Ltd | Equity | ₹182.4 Cr | 2.66% |
| Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹180.51 Cr | 2.63% |
| Abbott India Ltd | Equity | ₹174.58 Cr | 2.54% |
| Alembic Pharmaceuticals Ltd | Equity | ₹171.48 Cr | 2.50% |
| Pfizer Ltd | Equity | ₹166.32 Cr | 2.42% |
| Apollo Hospitals Enterprise Ltd | Equity | ₹158.02 Cr | 2.30% |
| Gland Pharma Ltd | Equity | ₹134.91 Cr | 1.97% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹131.36 Cr | 1.91% |
| Lupin Ltd | Equity | ₹129.2 Cr | 1.88% |
| AstraZeneca Pharma India Ltd | Equity | ₹126.8 Cr | 1.85% |
| Blue Jet Healthcare Ltd | Equity | ₹125.75 Cr | 1.83% |
| Indegene Ltd | Equity | ₹119.17 Cr | 1.74% |
| Metropolis Healthcare Ltd | Equity | ₹113.31 Cr | 1.65% |
| Rainbow Childrens Medicare Ltd | Equity | ₹88.55 Cr | 1.29% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹82.86 Cr | 1.21% |
| Thyrocare Technologies Ltd | Equity | ₹80.16 Cr | 1.17% |
| Aarti Drugs Ltd | Equity | ₹79.96 Cr | 1.17% |
| Medi Assist Healthcare Services Ltd | Equity | ₹72.77 Cr | 1.06% |
| Alivus Life Sciences Ltd | Equity | ₹66.27 Cr | 0.97% |
| Hikal Ltd | Equity | ₹64.87 Cr | 0.95% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹64.08 Cr | 0.93% |
| Manipal Health Enterprises Ltd | Equity | ₹59.96 Cr | 0.87% |
| Entero Healthcare Solutions Ltd | Equity | ₹50.92 Cr | 0.74% |
| Laxmi Dental Ltd | Equity | ₹46.5 Cr | 0.68% |
| FDC Ltd | Equity | ₹45.57 Cr | 0.66% |
| Windlas Biotech Ltd | Equity | ₹38.85 Cr | 0.57% |
| Indraprastha Medical Corp Ltd | Equity | ₹32.07 Cr | 0.47% |
| Indoco Remedies Ltd | Equity | ₹29.35 Cr | 0.43% |
| Natco Pharma Ltd | Equity | ₹1.36 Cr | 0.02% |
| Cash Margin - Derivatives | Cash - Collateral | ₹0.41 Cr | 0.01% |
Large Cap Stocks
23.35%
Mid Cap Stocks
31.98%
Small Cap Stocks
42.70%
AAA
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,703.27 Cr | 97.70% |
| Basic Materials | ₹82.86 Cr | 1.21% |
Standard Deviation
This fund
16.40%
Cat. avg.
16.41%
Lower the better
Sharpe Ratio
This fund
0.89
Cat. avg.
0.81
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.37
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GH2 | Expense Ratio 1.31% | Exit Load 1.00% | Fund Size ₹6,861 Cr | Age 8 years 3 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹12,32,494 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments